Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin

Gan, H. K., Parakh, S., Lassman, A. B., Seow, A., Lau, E., Lee, S. T., Ameratunga, M., Perchyonok, Y., Cao, D., Burvenich, I. J. G., O’Keefe, G. J., Rigopoulos, A., Gomez, E., Maag, D., & Scott, A. M. (2021). Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin. Neuro-Oncology Advances, 3(1). https://doi.org/10.1093/noajnl/vdab102
Authors:
Hui K Gan
Sagun Parakh
Andrew B Lassman
Aidan Seow
Eddie Lau
Sze Ting Lee
Malaka Ameratunga
Yuliya Perchyonok
Diana Cao
Ingrid J G Burvenich
Graeme J O'Keefe
Angela Rigopoulos
Erica Gomez
David Maag
Andrew M Scott
Affiliated Authors:
Andrew B Lassman
Author Keywords:
gbm
depatuxizumab mafadotin
tumor volume
Publication Type:
Article
Unique ID:
10.1093/noajnl/vdab102
PMID:
Publication Date:
Data Source:
PubMed

Record Created: